Combined treatment of acute maxillary sinusitis
https://doi.org/10.21518/2079-701X-2015-3-18-23
Abstract
Chronic rhinosinusitis is a relevant healthcare issue the incidence of which has increased twofold over the past 20 years. According to the literature, the incidence grows with age: in people aged 20 to 29 years, it equals 2.7%, and in people from 50 to 59 years - 6.6% [1]. Against a background of population ageing, inflammatory diseases of the paranasal sinuses (PNS) are becoming a challenge. Women suffer from chronic sinusitis 1.5 times more often than men. 15 to 36% of in-patients at ENT units are people suffering from diseases of the paranasal sinuses (PNS) [2].
About the Authors
A. I. Kryukov
Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
A. B. Turovskiy
Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
G. Y. Tsarapkin
Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
G. N. Izotova
Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
A. S. Tovmasyan
Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
K. M. Fedotkina
Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
D. S. Gorin
Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
References
1. Bebear CM, Renaudin H, Boudjadja A, Bebear C. In vitro activity of BAY 12-8039, a new fLuoro-quinoLone against mycopLasmas. Antimicrob Agents Chemother, 1998, 42: 703-4.
2. BLondeau J, Fass R. In vitro activity of BAY 12-8039, a new 8-methoxyquinoLone. Antimicrob Agents Chemother, 1997, 41: 1818-24.
3. LosaetaL Е, Woodcock J, Andrews J, BosweLL F, BrenwaLd N, Wise R. In vitro activity of BAY 12-8039, a new fLuoroquinoLone. Antimicrob Agents Chemother, 1997, 41: 101-6.
4. Duffy L, Kempf M, Crabb D, WaLL W, Herrington J. In vitro activity of moxifLoxacin and six other new antimicrobiaLs against MycopLasma pneu-moniae. Proceedings of the 39th ICAACf; 1999: 252, Sep 26-29; San Francisco.
5. ULLmann U, Schubert S, Krausse R. Comparative in-vitro activity of LevofLoxacin, other fLuoroquinoLones, doxycycLine and erythromycin against UreapLasma ureaLyticum and MycopLasma hominis. J Antimicrob Chemother 1999, 43(C): 33-6.
6. Gomez-Lus R, Adrian F, deL Campo R, et. aL. Comparative in vitro bacteriostatic and bactericidaL activity of trovafLoxacin, LevofLoxacin and moxifLoxacin against cLinicaL and environmentaL isoLates of LegioneLLa spp. Int J Antimicrob Agents, 2001, 18: 49-54.
7. Cohen R. The antibiotic treatment of acute oti-tis media and sinusitis in chiLdren. Diagn MicrobioL Infect Dis, 1997, 27: 49-53.
8. GwaLtney JM. Acute community-acquired sinusitis. CLin. Infect. Dis. 1996, 23: 12091223.
9. HampeL B. CLinicaL needs in the miLLennium -rhinosinusitis - the roLe of moxifLoxacin. - 1st Intern. MoxifLoxacin Symp., BerLin,1999, Ed. MandeLL L. Springer-VerLag, 2000: 174-177.
10. KLossek JM, Arvis P and study group. MoxifLoxacin versus trovafLoxacin in the treatment of acute bacteriaL maxiLLary sinusitis: a muLtinationaL, doubLe-bLind, randomised study. - 3rd Eur. Congr. Chemother., Madrid, 2000, Poster.
11. Stierna P. In: Kennedy DW, BoLger WE, Zinreich SJ, eds. Diseases of the sinuses: diagnosis and management. HamiLton, Ontario: B.C. Decker. 2001: 35-46.
12. Brannan MD, SeiberLing V, CutLer DL et aL. Lack of systemic activity with intranasaL mometa-sone furoate. Ann ALLergy Asthma ImmunoL, 1997, 97: 198.
13. Lund VJ, Kennedy DW. Ann OtoL RhinoL LaringoL, 1995, 167(h): 17-21.
Review
For citations:
Kryukov AI, Turovskiy AB, Tsarapkin GY, Izotova GN, Tovmasyan AS, Fedotkina KM, Gorin DS. Combined treatment of acute maxillary sinusitis. Meditsinskiy sovet = Medical Council. 2015;(3):18-23. (In Russ.) https://doi.org/10.21518/2079-701X-2015-3-18-23
Views:
551
Email this article 